Catalogs >
Abbott >
Alere™ q HIV-1/2 Detect

Alere™ q HIV-1/2 Detect
2Pages

Catalog excerpts

The challenges of early infant diagnosis of the 3.4 million children living with HIV do not receive ART.1 of children born to HIV positive mothers did not receive an HIV test within the first two months of life.1 of infants living with HIV die before the age of two, in the absence of timely HIV testing and antiretroviral therapy (ART).1 A more effective, faster alternative Current antibody tests are ineffective as they cannot discriminate between a mother’s and infant’s antibodies. Dry Blood Spot testing is usually done at 6 weeks and samples have to be transported for miles to a centralised laboratory. Weeks can go by before results are returned, when it is either too late or patients are lost to follow up. Alere~ q HIV-1/2 Detect provides access to testing and critical results in time to get children on treatment during the 8-12 week window of opportunity. Get molecular, virological results at the point of care, in 52 minutes, while mother and child are still present.

Open the catalog to page 1

Accessible Molecular Testing in 52 minutes ACCESSIBLE Take molecular HIV testing where it’s needed most Save time, save lives; get reliable molecular results in under an hour Robust build quality, wherever it’s needed Real-time polymerase chain reaction (RT-PCR) with multiplexing capability Minimal training is required Large, guided touchscreen is intuitive and simple Current alternatives takes days, even weeks to transport samples and receive results - and delays in treatment can be deadly Automated isolation and detection of nucleic acid Next generation technology at the point of care...

Open the catalog to page 2